GlassScriptPhysician profile
Gary J Lau
NPI 1427049568
$3,171.84
in general payments reported to CMS, 2019-2025
27 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $214 · 2021: $531 · 2022: $659 · 2023: $374 · 2024: $458 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $691.23 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Alcon Vision LLC | $437.39 | 2020-2025 | Hydrus Microstent, Voyager Dslt |
| Genzyme Corporation | $226.12 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $196.83 | 2019-2021 | |
| Abbvie INC. | $166.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $137.13 | 2019-2023 | Eylea Hd |
| Ocular Therapeutix, INC. | $134.13 | 2024 | Dextenza |
| Bausch & Lomb Americas INC. | $124.98 | 2024 | Xiidra, Miebo |
| Horizon Therapeutics Plc | $122.81 | 2021 | |
| Mallinckrodt Hospital Products INC. | $122.68 | 2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $94.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $84.87 | 2019-2020 | |
| Daiichi Sankyo INC. | $82.96 | 2021 | |
| Glaukos Corporation | $70.31 | 2025 | Idosetr, Istent Infinite |
| Vifor Pharma, INC. | $63.54 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $56.63 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $48.65 | 2019 | |
| Biotissue Holdings INC. | $48.63 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $44.48 | 2019 | |
| Alnylam Pharmaceuticals INC. | $40.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.69 | 2019 | |
| Rxsight INC | $34.21 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $25.97 | 2019-2023 | Cequa |
| Genentech USA, INC. | $25.38 | 2025 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $20.42 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $19.76 | 2025 | Tyrvaya, Ryzumvi |
| Apellis Pharmaceuticals, INC. | $16.38 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.